Cargando…
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
BACKGROUND: Breast cancers due to germline mutations or altered expression of the BRCA1 gene associate with an aggressive clinical course and frequently exhibit a "triple-negative" phenotype, i.e. lack of expression of the estrogen and progesterone hormone receptors and lack of overexpress...
Autores principales: | Alli, Elizabeth, Sharma, Vandana B, Hartman, Anne-Renee, Lin, Patrick S, McPherson, Lisa, Ford, James M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146825/ https://www.ncbi.nlm.nih.gov/pubmed/21771338 http://dx.doi.org/10.1186/1471-2210-11-7 |
Ejemplares similares
-
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016) -
Effects of BRCA1 Transgene Expression on Murine Mammary Gland Development and Mutagen-Induced Mammary Neoplasia
por: Hoshino, Arichika, et al.
Publicado: (2007) -
Phosphoproteomics reveals network rewiring to a pro-adhesion state in annexin-1-deficient mammary epithelial cells
por: Alli-Shaik, Asfa, et al.
Publicado: (2017) -
BRCA1: a movement toward cancer prevention
por: Alli, Elizabeth, et al.
Publicado: (2015) -
Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice
por: Collins, NK, et al.
Publicado: (2000)